This triple drug regimen became the first FDA-approved all-oral combination for multiple myeloma in the relapsed/refractory setting.
Women who underwent bilateral oophorectomy were at greater risk than those who only had 1 ovary removed.
Clinicians seek stronger collaboration between cardiology and oncology as well as evidence-based treatment guidelines.
Dr Jabbour discusses clinical decision making for chronic myeloid leukemia and the high price of newly approved drugs in an interview with Cancer Therapy Advisor.
Recent research has indicated the potential for IL-12 therapy to be effective in combination with new and emerging biologics including other immunomodulatory drugs.
Acute kidney injury incidence after radical nephrectomy and partial nephrectomy is increasing.
From Oncology Nurse Advisor
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Navigating the 2016 ASCO Annual Meeting: Immunotherapy, Precision Medicine 'Significant Themes'
- Ribociclib Improves PFS in Treatment-naïve Patients With Advanced Breast Cancer
- Body Mass Index Associated With Colorectal Cancer Mortality Risk
- Adding RT to Surgery Improves Survival in Retroperitoneal Sarcoma
- Health Care Workplace Violence: "Underreported, Tolerated, and Largely Ignored"
- Breast Cancer (Recurrent or Metastatic) Treatment Regimens
- New Surgical System Offers Alternative to Lumpectomy Wire Localization
- Testicular Cancer Treatment Regimens
- Arsenic Levels in Drinking Water Tied to Elevated Bladder Cancer Risk
- Four Quality Measures May Lengthen Survival in Patients With NSCLC
- Ixazomib Plus Lenalidomide/Dexamethasone Effective in Relapsed, Refractory Multiple Myeloma
- First-line Dasatinib Safe, Effective for Long-term Treatment of CML-CP
- Psychosocial, Demographic Factors Related to Worry in Patients With Melanoma Identified
- Oophorectomy Associated With 30% Increased Risk for Women With Colorectal Cancer
- Myeloma: Daratumumab Monotherapy Induces Rapid, Deep, Durable Responses